BetterLife Pharma Inc. (BETRF)
OTC Markets OTCQB
Price as at 30 Sept 2026, 16:26 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
BetterLife Pharma Inc. trades at $0.21. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About BetterLife Pharma Inc.
BetterLife Pharma Inc., a biotechnology company, engages in the development of psychedelic-derived compounds. It focuses on developing and commercializing BETR-001, a non-hallucinogenic and non-controlled LSD derivative to treat neuro-psychiatric and neurological disorders. Its products also comprise MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia; and MM-003, a patent pending proprietary interferon alpha-2b inhalation formulation. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Common questions
Where does SteadyShares get its BETRF data?
Fundamentals for BETRF come from company filings and exchange data, as listed on OTC Markets OTCQB; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 16:26 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for BETRF, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.